NeuroSense Therapeutics Ltd. (NRSNW) NASDAQ
0.13
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.13
+0(+0.00%)
Currency In USD
Address
Medinat ha-Yehudim Street 85
Herzliya, 4676670
Israel
Phone
972 9 953 1142
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
December 09, 2021
| Name | Title | Pay | Year Born |
| Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director | 392,000 | 1979 |
| Niva Russek-Blum | Chief Technology Officer | 201,000 | 1979 |
| Or Eisenberg | Chief Financial Officer | 273,000 | 1981 |
| Ferenc Tracik | Chief Medical Officer | 447,000 | 1964 |
| Keren Pushett | Head of HR | 0 | N/A |
| Yael Barak | Vice President of Quality & Compliance | 0 | 1970 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.